MET and non-small cell lung carcinoma: MET inhibitors have demonstrated clinical benefit in NSCLC with MET exon 14 (METex14) skipping alterations, leading to regular approval of capmatinib and tepotinib, while crizotinib received FDA breakthrough therapy designation for this indication.